Knight Cancer Institute

Research Output 1990 2019

Filter
Comment/debate
2019
1 Citation (Scopus)

Cancer screening: A modest proposal for prevention

Kim, M. S., Nishikawa, G. & Prasad, V., Mar 1 2019, In : Cleveland Clinic journal of medicine. 86, 3, p. 157-160 4 p.

Research output: Contribution to journalComment/debate

Open Access
Early Detection of Cancer

Erratum: Correction: FGF2-FGFR1 signaling regulates release of leukemia-protective exosomes from bone marrow stromal cells (eLife (2019) 8 PII: e47174)

Javidi-Sharifi, N., Martinez, J., English, I., Joshi, S. K., Scopim-Ribeiro, R., Viola, S. K., Edwards, D. K., Agarwal, A., Lopez, C., Jorgens, D., Tyner, J., Druker, B. & Traer, E., Mar 29 2019, In : eLife. 8

Research output: Contribution to journalComment/debate

Open Access
Exosomes
Fibroblast Growth Factor 2
Mesenchymal Stromal Cells
Medicine
Bone

Publisher Correction: Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer (Nature Communications, (2019), 10, 1, (766), 10.1038/s41467-019-08595-2)

Merino, D., Weber, T. S., Serrano, A., Vaillant, F., Liu, K., Pal, B., Di Stefano, L., Schreuder, J., Lin, D., Chen, Y., Labat, M-L., Schumacher, T. N., Cameron, D., Smyth, G. K., Papenfuss, A. T., Lindeman, G. J., Visvader, J. E. & Naik, S. H., Dec 1 2019, In : Nature communications. 10, 1, 1945.

Research output: Contribution to journalComment/debate

Open Access
Triple Negative Breast Neoplasms
Heterografts
histograms
breast
cancer

Registration studies — when should patients be deemed ineligible for aggressive therapy?

Cook, R. J., Gill, J. & Prasad, V., Jan 1 2019, In : Nature Reviews Clinical Oncology.

Research output: Contribution to journalComment/debate

Therapeutics

Testing for blinding in sham-controlled studies for procedural interventions: The third-party video method

Gill, J. & Prasad, V., Mar 11 2019, In : CMAJ. 191, 10, p. E272-E273

Research output: Contribution to journalComment/debate

2018
2 Citations (Scopus)

A novel AGGF1-PDGFRβ fusion in pediatric T-cell acute lymphoblastic leukemia

Zabriskie, M. S., Antelope, O., Verma, A. R., Draper, L. R., Eide, C. A., Pomicter, A. D., Tran, T. H., Druker, B., Tyner, J., Miles, R. R., Graham, J. M., Hwang, J. Y., Varley, K. E., Toydemir, R. M., Deininger, M. W., Raetz, E. A. & O’Hare, T., Jan 31 2018, In : Haematologica. 103, 2, p. e87-e91

Research output: Contribution to journalComment/debate

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Pediatrics
3 Citations (Scopus)

Choice of control group in randomised trials of cancer medicine: are we testing trivialities?

Tao, D. & Prasad, V., Sep 1 2018, In : The Lancet Oncology. 19, 9, p. 1150-1152 3 p.

Research output: Contribution to journalComment/debate

Medicine
Control Groups
Neoplasms

Competing immune biomarkers in the selection of first-line therapy in non-small cell lung cancer

Tolba, K., Jan 1 2018, In : European Oncology and Haematology. 14, 2, p. 67-69 3 p.

Research output: Contribution to journalComment/debate

Non-Small Cell Lung Carcinoma
Biomarkers
Therapeutics
pembrolizumab
3 Citations (Scopus)

Concerns about the approval of nusinersen sodium by the US food and drug administration

Gerrity, M. S., Prasad, V. & Obley, A. J., Jun 1 2018, In : JAMA Internal Medicine. 178, 6, p. 743-744 2 p.

Research output: Contribution to journalComment/debate

United States Food and Drug Administration
Sodium
2 Citations (Scopus)

Erratum: Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (Cell (2018) 174(3) (758–769.e9), (S0092867418308420) (10.1016/j.cell.2018.06.039))

Quigley, D. A., Dang, H. X., Zhao, S. G., Lloyd, P., Aggarwal, R., Alumkal, J., Foye, A., Kothari, V., Perry, M. D., Bailey, A. M., Playdle, D., Barnard, T. J., Zhang, L., Zhang, J., Youngren, J. F., Cieslik, M. P., Parolia, A., Beer, T. T., Thomas, G., Chi, K. N. & 43 othersGleave, M., Lack, N. A., Zoubeidi, A., Reiter, R. E., Rettig, M. B., Witte, O., Ryan, C. J., Fong, L., Kim, W., Friedlander, T., Chou, J., Li, H., Das, R., Li, H., Moussavi-Baygi, R., Goodarzi, H., Gilbert, L. A., Lara, P. N., Evans, C. P., Goldstein, T. C., Stuart, J. M., Tomlins, S. A., Spratt, D. E., Cheetham, R. K., Cheng, D. T., Farh, K., Gehring, J. S., Hakenberg, J., Liao, A., Febbo, P. G., Shon, J., Sickler, B., Batzoglou, S., Knudsen, K. E., He, H. H., Huang, J., Wyatt, A. W., Dehm, S. M., Ashworth, A., Chinnaiyan, A. M., Maher, C. A., Small, E. J. & Feng, F. Y., Oct 18 2018, In : Cell. 175, 3, 1 p.

Research output: Contribution to journalComment/debate

Genomic Structural Variation
Manuscripts
Amplification
Prostatic Neoplasms
Statistical tests
7 Citations (Scopus)

Erratum: Comprehensive Characterization of Cancer Driver Genes and Mutations (ARTICLE (2018) 173(2) (371–385), (S009286741830237X), (10.1016/j.cell.2018.02.060))

The MC3 Working Group & The Cancer Genome Atlas Research Network, Aug 9 2018, In : Cell. 174, 4, p. 1034-1035 2 p.

Research output: Contribution to journalComment/debate

Neoplasm Genes
Adenocarcinoma
Genes
Mutation
ethyl-2-methylthio-4-methyl-5-pyrimidine carboxylate
5 Citations (Scopus)

Erratum: The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (Cell Reports (2018) 23(1) (313–326.e5) (S2211124718304364) (10.1016/j.celrep.2018.03.075))

The Cancer Genome Atlas Research Network & The Cancer Genome Atlas Research Network, Jun 19 2018, In : Cell Reports. 23, 12, 1 p.

Research output: Contribution to journalComment/debate

Atlases
Renal Cell Carcinoma
Names
Emotions
Genes
5 Citations (Scopus)

Improving observational studies in the era of big data

Gill, J. & Prasad, V., Sep 1 2018, In : The Lancet. 392, 10149, p. 716-717 2 p.

Research output: Contribution to journalComment/debate

Observational Studies
4 Citations (Scopus)

Pemetrexed in nonsquamous non-small-cell lung cancer: The billion dollar subgroup analysis

Gyawali, B. & Prasad, V., Jan 1 2018, In : JAMA oncology. 4, 1, p. 17-18 2 p.

Research output: Contribution to journalComment/debate

Pemetrexed
Non-Small Cell Lung Carcinoma
31 Citations (Scopus)

Tisagenlecleucel - The first approved CAR-T-cell therapy: Implications for payers and policy makers

Prasad, V., Jan 1 2018, In : Nature Reviews Clinical Oncology. 15, 1, p. 11-12 2 p.

Research output: Contribution to journalComment/debate

Cell- and Tissue-Based Therapy
Administrative Personnel
T-Lymphocytes
2017
12 Citations (Scopus)

Clinical trial enrollment of adolescents and young adults with sarcoma

Davis, L., Janeway, K. A., Weiss, A. R., Chen, Y. L. E., Scharschmidt, T. J., Krailo, M., Glade Bender, J. L., Kopp, L. M., Patel, S. R., Schwartz, G. K., Horvath, L. E., Hawkins, D. S., Chuk, M. K., Reinke, D. K., Gorlick, R. G. & Randall, R. L., Sep 15 2017, In : Cancer. 123, 18, p. 3434-3440 7 p.

Research output: Contribution to journalComment/debate

Sarcoma
Young Adult
Clinical Trials
Publications
Neoplasms
6 Citations (Scopus)

Drugs that lack single-agent activity: Are they worth pursuing in combination?

Gyawali, B. & Prasad, V., Apr 1 2017, In : Nature Reviews Clinical Oncology. 14, 4, p. 193-194 2 p.

Research output: Contribution to journalComment/debate

Pharmaceutical Preparations
3 Citations (Scopus)

Pembrolizumab as first-line therapy in programmed death ligand 1–positive advanced lung cancer: Is it as effective as we think it is?

Goldstein, D. A., Bilal, U. & Prasad, V., Oct 15 2017, In : Cancer. 123, 20, p. 3872-3874 3 p.

Research output: Contribution to journalComment/debate

Lung Neoplasms
Ligands
Therapeutics
pembrolizumab
2016
1 Citation (Scopus)

Cover Image, Volume 171B, Number 6, September 2016

IMAGE2 Consortium & German ADHD GWAS Group, Sep 1 2016, In : American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics. 171, 6, p. 1 1 p.

Research output: Contribution to journalComment/debate

Erratum: A new era for hemophilia B treatment (Blood (2016) 127:14 (1734-1736))

Taylor, J. & Kruse-Jarres, R., Oct 13 2016, In : Blood. 128, 15, p. 1994 1 p.

Research output: Contribution to journalComment/debate

Hemophilia B
Blood
92 Citations (Scopus)

Perspective: The precision-oncology illusion

Prasad, V., Sep 7 2016, In : Nature. 537, 7619, p. S63

Research output: Contribution to journalComment/debate

Molecular Targeted Therapy
Precision Medicine
Medical Oncology
Genetic Testing
Reproducibility of Results

Precision medicine in diffuse large B-cell lymphoma: Hype or hope?

Prasad, V., Nov 1 2016, In : European Journal of Cancer. 68, p. 22-26 5 p.

Research output: Contribution to journalComment/debate

Precision Medicine
Lymphoma, Large B-Cell, Diffuse
3 Citations (Scopus)

Same data; Different interpretations

Bishal Gyawali, G. & Prasad, V., Nov 1 2016, In : Journal of Clinical Oncology. 34, 31, p. 3729-3732 4 p.

Research output: Contribution to journalComment/debate

2 Citations (Scopus)

Thinking systematically about the off-label use of cancer drugs and combinations for patientswho have exhausted proven therapies

Mailankody, S. & Prasad, V., Sep 1 2016, In : Oncologist. 21, 9, p. 1031-1032 2 p.

Research output: Contribution to journalComment/debate

Off-Label Use
Drug Combinations
Neoplasms
Therapeutics